Efficient In Vitro TRAIL-Gene Delivery in Drug-Resistant A2780DDP Ovarian Cancer Cell Line via Magnetofection

Abstract EN

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) presents great promise as an anticancer agent for human cancer therapy.

In this study, a magnetofection agent (polyMAG-l000) was evaluated for in vitro delivery of TRAIL gene towards drug-resistant A2780/DDP ovarian cancer cells.

Transfection experiments showed that polyMAG-l000 was able to transfect A2780/DDP cells in vitro, leading to a higher level of TRAIL gene expression in the presence of a static magnetic field as compared to other transfection agent, such as Lipofectamine 2000.

TRAIL gene expression in the A2780/DDP cells was also confirmed by Western blot analysis.

Moreover, the TRAIL gene expression exhibited remarkable decrease in the cell viability, as determined by MTT assay.

Importantly, PolyMAG-l000-mediated TRAIL gene transfection in the presence of anticancer drug cisplatin (CDDP) induced much higher percentages of apoptotic A2780/DDP cells, compared to TRAIL gene transfection or CDDP treatment alone.

A further study by Western blot analysis indicated that cytochrome c release and caspase-9 cleavage pathway were associated with the initiation of the apoptosis in A2780/DDP cells.

The results of this study indicate that polyMAG-l000 can be used as an efficient agent for TRAIL gene transfection in ovarian cancer cells.